The coexistence of hypertrophic cardiomyopathy and hypertension affects 40–60% of adults with HCM, leading to greater functional limitations and cardiometabolic comorbidities.
The coexistence of HCM and hypertension affects 40-60% of adults with HCM, complicating diagnosis and management, and highlighting the need for careful pharmacologic selection.
Absolute Event Rate: 0% vs 0%
Background: Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease. Arterial hypertension represents the leading modifiable risk factor for cardiovascular morbidity and mortality globally. Their coexistence is frequent, affecting approximately 40–60% of adults with HCM, yet the implications of this overlap remain insufficiently investigated. Methods: We conducted a narrative review of the existing literature addressing the clinical profile and management strategies in patients with concomitant HCM and hypertension. Particular emphasis was placed on pharmacologic treatment and the role of emerging therapies for this population. Results: Patients with both conditions are generally older, with more cardiometabolic comorbidities and greater functional limitation than those with isolated HCM. Hypertension may confound diagnosis and is linked to a higher prevalence of atrial fibrillation and stroke. Its effect on ventricular arrhythmias, sudden cardiac death and mortality is less clear. Management is challenging, as vasodilatory antihypertensives can exacerbate left ventricular outflow tract obstruction. β-blockers and non-dihydropyridine calcium channel blockers are preferred, while novel agents such as myosin inhibitors and SGLT2 inhibitors show potential but require further study. Conclusions: The coexistence of HCM and hypertension is frequent but insufficiently studied, with major implications for diagnosis and treatment. Further research is essential to optimize management and outcomes.
Katsi et al. (Mon,) reported a other. The coexistence of hypertrophic cardiomyopathy and hypertension affects 40–60% of adults with HCM, leading to greater functional limitations and cardiometabolic comorbidities.